Alexandra Sinclair
Founder, Executive Director, Chief Scientific Officer / Invex Therapeutics
Professor Alexandra Sinclair, founder of Invex Therapeutics, is a clinician scientist and neurology consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences at The University of Birmingham in UK. Prof Sinclair and her research group hosted a high profile visit from NASA, who are interested in her discovery of the novel use of Glucogon-like peptide 1 receptor agonists to reduce intracranial pressure which are of particular interest to the NASA team in their quest to reduce brain pressure during long duration space travel and allow them to go beyond the Moon.
